ZEALAND PHARMA A/S

ZEAL
Delayed Quote. Delayed  - 01/21 10:59:43 am
131.6DKK -4.64%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 8 7665 688
Enterprise Value (EV)1 7 6384 921
P/E ratio -10,00x-4,58x
Yield --
Capitalization / Revenue 24,8x19,5x
EV / Revenue 21,6x16,9x
EV / EBITDA -10,2x-4,76x
Price to Book 6,89x4,45x
Nbr of stocks (in thousands) 39 73543 225
Reference price (DKK) 221132
Announcement Date 03/11/2021-
Previous period Next period
1 DKK in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 353291
EBITDA1 -750-1 034
Operating profit (EBIT)1 -792-1 032
Operating Margin -224%-355%
Pre-Tax Profit (EBT)1 -840-1 008
Net income1 -847-1 007
Net margin -240%-346%
EPS2 -22,1-28,8
Dividend per Share2 --
Announcement Date 03/11/2021-
Previous period Next period
1 DKK in Million
2 DKK
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 1 127767
Leverage (Debt / EBITDA) 1,50x0,74x
Free Cash Flow1 -714-1 016
ROE (Net Profit / Equities) -68,5%-87,4%
Shareholders' equity1 1 2361 152
ROA (Net Profit / Asset) -50,4%-66,3%
Assets1 1 6811 518
Book Value Per Share2 32,029,6
Cash Flow per Share2 -17,9-39,6
Capex1 25,032,0
Capex / Sales 7,09%11,0%
Announcement Date 03/11/2021-
Previous period Next period
1 DKK in Million
2 DKK
Financial Ratios
Size 2021e 2022e
Capitalization 5 688 M DKK -
Enterprise Value (EV) 4 921 M DKK 5 154 M DKK
Valuation 2021e 2022e
P/E ratio (Price / EPS) -4,58x -4,79x
Capitalization / Revenue 19,5x 13,0x
EV / Revenue 16,9x 11,2x
EV / EBITDA -4,76x -4,67x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 4,45x 18,3x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -355% -245%
Operating Leverage (Delta EBIT / Delta Sales) -1,72x -
Net Margin (Net Profit / Revenue) -346% -246%
ROA (Net Profit / Asset) -66,3% -76,4%
ROE (Net Profit / Equities) -87,4% -147%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   11,0% 7,45%
Cash Flow / Sales -588% -397%
Capital Intensity (Assets / Sales) 5,22x 3,22x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend